A recently published article in the European Heart Journal shows that the presence of sticky, aggregation-prone LDL in circulation is an independent predictor of cardiovascular death. This novel finding indicates that in ...
Jul 12, 2018
0
11
A team of researchers affiliated with several institutions in China has identified a gene mutation that is at least partly responsible for regulating cholesterol levels in the bloodstream. In their paper published in the ...
Lipoprotein(a) is a variant of LDL (low-density lipoprotein) cholesterol, and large amounts of data have shown that higher lipoprotein(a) levels are associated with an increased risk of cardiovascular events. Atherosclerosis ...
May 21, 2018
0
10
A new study by UMass Medical School physician-scientist Benjamin U. Nwosu, MD, finds that children with type 1 diabetes who experienced a partial clinical remission, or "honeymoon phase," had significantly lower low-density ...
May 17, 2018
0
30
Cholesterol-lowering drugs are more likely to save thousands of additional lives when used in people with higher levels of LDL cholesterol, or "bad" cholesterol, according to a new study from the University of Iowa, published ...
Apr 17, 2018
0
6
Despite heart disease and type 2 diabetes being among the leading causes of death in the U.S., the mechanisms leading to and linking these two diseases remain incompletely understood. A new study by investigators at Brigham ...
Apr 10, 2018
0
3
PCSK9 inhibition is a new therapeutic strategy for atherosclerosis which is known to lower LDL cholesterol. Research from Karolinska Institutet, presented at the ESC Congress last year and now published in the Journal of ...
Apr 6, 2018
0
4
Less than 40 percent of people with severe elevations in cholesterol are being prescribed appropriate drug treatment, according to a nationally representative study reported in the American Heart Association's journal Circulation.
Mar 26, 2018
0
4
Among patients with persistently high cholesterol despite high-intensity statin therapy, the proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitor alirocumab reduced rates of major adverse cardiovascular events (MACE) ...
Mar 12, 2018
0
5
The anti-cholesterol drug Praluent (alirocumab), made by France's Sanofi Pharmaceuticals, is linked to a 15 percent lower risk of major cardiovascular events like heart attack and stroke, a study said Saturday.
Mar 10, 2018
0
86
